Selective granulocyte and monocyte apheresis as a non-pharmacological option for patients with inflammatory bowel disease

Transfusion Medicine and Hemotherapy

Volumn 39, Issue 4, 2012, Pages 246-252

  Leitner, Gerda C ^a   Worel, Nina ^a   Vogelsang, Harald ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adacolumn ; Cellsorba ; Inflammatory bowel disease; Selective granulocyte and monocyte cell adsorption

Indexed keywords

ACETYLSALICYLIC ACID; CELLULOSE ACETATE; CYCLOSPORIN A; HEPARIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; MESALAZINE; NAFAMOSTATE MESILATE; PREDNISOLONE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; APOPTOSIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CROHN DISEASE; CYTOKINE RELEASE; DENDRITIC CELL; DIZZINESS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENTERITIS; FEVER; FILTER; GRANULOCYTE; GRANULOCYTE MONOCYTE APHERESIS; HEADACHE; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HEPATITIS C; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOADSORBENT; IMMUNOADSORPTION; LEACHING; LEUKAPHERESIS; LYMPHOCYTOPENIA; MONITOR; MONOCYTE; NAUSEA; NEUTROPHIL CHEMOTAXIS; PROTEIN EXPRESSION; PSORIASIS; PUMP; PYODERMA; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; THROMBOCYTE COUNT; TREATMENT INDICATION; TREATMENT OUTCOME; TUBE; ULCERATIVE COLITIS;

EID: 84865422636     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000341801     Document Type: Review

References (58)

1. Saniabadi AR, Hanai H: Therapeutic apheresis from the early civilizations to the twenty-first century. Gastroenterol Clin Biol 2010;34:645-648.
2. Straube R, Donate H-P, Hager U, Bak K: Vom Aderlass zur Apherese. 2010.
3. Grisham MB, Yamada T: Neutrophils, nitrogen oxides, and inflammatory bowel disease. Ann N Y Acad Sci 1992;664:103-115. (Pubitemid 23022842)
4. Grisham MB, Granger N: Mechanisms of neutrophil-mediated tissue injury; in MacDermott RP, Stenson WF (eds): Inflammatory Bowel Disease. New York, Elsevier, 1992, pp 225-239.
5. Sandborn WJ: Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis 2006;12(suppl 1):S15-21. (Pubitemid 43068430)
6. Brannigan AE, O'Connell PR, Hurley H, O'Neill A, Brady HR, Fitzpatrick JM, Watson RW: Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 2000;13:361-366.
7. Meuret G, Bitzi A, Hammer B: Macrophage turnover in Crohn's disease and ulcerative colitis. Gastroenterology 1978;74:501-503. (Pubitemid 8276540)
8. Papadakis KA, Targan SR: Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000;51:289-298. (Pubitemid 30216038)
9. Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, Groessner B, Lochs H, Raedler A: Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999;353:459-461. (Pubitemid 29067338)
10. Bicks RO, Groshart KD: The current status of Tlymphocyte apheresis (TLA) treatment of Crohn's disease. J Clin Gastroenterol 1989;11:136-138. (Pubitemid 19104432)
11. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476. (Pubitemid 41770166)
12. Stein RB, Hanauer SB: Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000;23:429-448.
13. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-936. (Pubitemid 351451967)
14. Hyde GM, Thillainayagam AV, Jewell DP: Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998;10:411-413. (Pubitemid 28241428)
15. Kornbluth A, Marion JF, Salomon P, Janowitz HD: How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials. J Clin Gastroenterol 1995; 20:280-284.
16. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH: Guidelines on the use of therapeutic apheresis in clinical practice -evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25:83-177.
17. Sands BE, Sandborn WJ, Feagan B, Lofberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S: A randomized, doubleblind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008;135:400-409.
18. Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R: Adacolumn for selective leukocytapheresis as a nonpharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher 2005;20:171-184. (Pubitemid 43081867)
19. Hanai H: Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006;12:7568-7577. (Pubitemid 46040566)
20. Hanai H, Iida T, Yamada M, Sato Y, Takeuchi K, Tanaka T, Kondo K, Kikuyama M, Maruyama Y, Iwaoka Y, Nakamura A, Hirayama K, Saniabadi AR, Watanabe F: Effects of Adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis. World J Gastroenterol 2006;12:3393-3399. (Pubitemid 43933785)
21. Kashiwagi N, Sugimura K, Koiwai H, Yamamoto H, Yoshikawa T, Saniabadi AR, Adachi M, Shimoyama T: Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002; 47:1334-1341. (Pubitemid 34606638)
22. Kuijpers TW, Tool AT, van der Schoot CE, Ginsel LA, Onderwater JJ, Roos D, Verhoeven AJ: Membrane surface antigen expression on neutrophils: a reappraisal of the use of surface markers for neutrophil activation. Blood 1991;78:1105-1111.
23. Ramlow W, Emmrich J, Ahrenholz P, Sparmann G, Kashiwagi N, Franz M, Yokoyama T, Yoshikawa T: In vitro and in vivo evaluation of Adacolumn cytapheresis in healthy subjects. J Clin Apher 2005;20:72-80. (Pubitemid 41297411)
24. Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R: The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2010; 163: 50-58.
25. Raffler NA, Riviera-Nieves J, Ley K: L-selectin in inflammation, infection and immunity. Drug Discov Today 2005;2:213-220. (Pubitemid 41488154)
26. Waitz G, Petermann S, Liebe S, Emmrich J, Ramlow W: Reduction of dendritic cells by granulocyte and monocyte adsorption apheresis in patients with ulcerative colitis. Dig Dis Sci 2008;53:2507-2515.
27. Cuadrado E: Granulocyte/monocyte apheresis as immunotherapic tool: cellular adsorption and immune modulation. Autoimmun Rev 2009;8: 292-296.
28. Cuadrado E, Alonso M, de Juan MD, Echaniz P, Arenas JI: Regulatory T cells in patients with inflammatory bowel diseases treated with Adacolumn granulocytapheresis. World J Gastroenterol 2008;14:1521-1527. (Pubitemid 351460165)
29. Biagi E, Di Biaso I, Leoni V, Gaipa G, Rossi V, Bugarin C, Renoldi G, Parma M, Balduzzi A, Perseghin P, Biondi A: Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graftversus-host disease. Transplantation 2007;84:31-39. (Pubitemid 47094638)
30. Di Biaso I, Di Maio L, Bugarin C, Gaipa G, Dander E, Balduzzi A, Parma M, D'Amico G, Perseghin P, Biondi A, Biagi E: Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation 2009;87:1422-1425.
31. Beretta A, Clerici M, Hasson H, Fumagalli L, Trabattoni D, Lillo F, Ferrante P, Saniabadi AR, Adachi M, Lazzarin A: Ex-vivo purging of circulating monocytes results in immunovirologic improvement in partially HAART responder HIV-infected patients. J Biol Regul Homeost Agents 2000;14:27-31. (Pubitemid 32288561)
32. Yamamoto T, Umegae S, Matsumoto K: Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis. World J Gastroenterol 2006;12:520-525. (Pubitemid 43380780)
33. Maruyama Y, Yoshida H, Uchino S, Yokoyama K, Yamamoto H, Takinami M, Hosoya T: Nafamostat mesilate as an anticoagulant during continuous venovenous hemodialysis: a three-year retrospective cohort study. Int J Artif Organs 2011;34:571-576.
34. Hetzel GR, Sucker C: The heparins: all a nephrologist should know. Nephrol Dial Transplant 2005; 20:2036-2042. (Pubitemid 41510075)
35. Takahashi H, Muto S, Nakazawa E, Yanagiba S, Masunaga Y, Miyata Y, Tamba K, Kusano E, Matsuo M, Matsuo T, Asano Y: Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient. Clin Nephrol 2003;59:458-462. (Pubitemid 36722328)
36. Shibata H, Kuriyama T, Yamawaki N: Cellsorba. Ther Apher Dial 2003;7:44-47. (Pubitemid 36648042)
37. Irving PM, Macey MG, Shah U, Webb L, Langmead L, Rampton DS: Formation of platelet-leukocyte aggregates in inflammatory bowel disease. Inflamm Bowel Dis 2004;10:361-372. (Pubitemid 39029179)
38. Passacquale G, Vamadevan P, Pereira L, Hamid C, Corrigall V, Ferro A: Monocyte-platelet interaction induces a pro-inflammatory phenotype in circulating monocytes. PLoS One2011;6:e25595.
39. Calzascia T, Pellegrini M, Lin A, Garza KM, Elford AR, Shahinian A, Ohashi PS, Mak TW: CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc Natl Acad Sci U S A 2008;105:2999-3004. (Pubitemid 351723657)
40. Schulze-Koops H: Lymphopenia and autoimmune diseases. Arthritis Res Ther 2004;6:178-180. (Pubitemid 39162381)
41. Le Campion A, Gagnerault MC, Auffray C, Becourt C, Poitrasson-Riviere M, Lallemand E, Bienvenu B, Martin B, Lepault F, Lucas B: Lymphopenia-induced spontaneous T-cell proliferation as a cofactor for autoimmune disease development. Blood 2009;114:1784-1793.
42. Danese S, Angelucci E, Stefanelli T, Omodei P, Luigiano C, Finazzi S, Pagano N, Repici A, Vecchi M, Malesci A: Cytapheresis in inflammatory bowel diseases: current evidence and perspectives. Digestion 2008;77:96-107. (Pubitemid 351556387)
43. Triantafillidis JK, Cherakakis P: Current status on the clinical usefulness of apheresis in patients with inflammatory bowel disease. Ann Gastroenterol 2003;16:100-104.
44. Zhu M, Xu X, Nie F, Tong J, Xiao S, Ran Z: The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis. Int J Colorectal Dis 2011;26:999-1007.
45. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F: Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009;15:1851-1858.
46. Best WR, Becktel JM, Singleton JW, Kern F Jr: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-444.
47. Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, Numata Y, Kuga Y, Moriya T, Ohya T, Kajiyama G: In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naive patients. Dig Liver Dis 2008;40:731-736.
48. Yamamoto T, Umegae S, Matsumoto K: Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis 2010; 16:1905-1911.
49. Habermalz B, Sauerland S: Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis. Dig Dis Sci 2010;55:1421-1428.
50. Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S: Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther 2010;31:1286-1295.
51. Abreu MT PS, Sands BE, Weinstein R: selektive leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007;41:874-888. (Pubitemid 350307073)
52. Fujimori J, Yoshino S, Koiwa M, Hirai H, Shiga H, Hayama N, Iino Y: Improvement in rheumatoid arthritis following application of an extracorporeal granulotrap column, G-1. Rheumatol Int 1996;15: 175-180. (Pubitemid 126806104)
53. Nagashima M, Yoshino S, Tanaka H, Yoshida N, Kashiwagi N, Saniabadi AR: Granulocyte and monocyte apheresis suppresses symptoms of rheumatoid arthritis: a pilot study. Rheumatol Int 1998; 18:113-118. (Pubitemid 28505333)
54. Ohara M, Saniabadi AR, Kokuma S, Hirata I, Adachi M, Agishi T, Kasukawa R: Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 1997;21:989-994. (Pubitemid 27380936)
55. Sawada K: Leukocytapheresis as an adjunct to conventional medication for inflammatory bowel disease. Dis Colon Rectum 2003;46(10 suppl):S66-77. (Pubitemid 37266362)
56. Sawada K, Kashiwamura S, Okamura H, Ohnishi K, Fukunaga K, Hirata I, Saniabadi A: Selective granulocyte and monocyte apheresis as a new adjunct to enhance the efficacy of interferon-alpha + ribavirin in patients with high plasma hepatitis C virus. Dig Liver Dis 2005;37: 515-521. (Pubitemid 44356057)
57. Ljung T, Thomsen OØ, Vatn M, Karlén P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Löfberg R: Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007;42:221-227.
58. North East Treatment Advisory Group (NETAG): Leukapheresis with Adacolumn® for Inflammatory Bowel Disease. 2011, pp 1-24.